Family Communication Intervention for Dilated Cardiomyopathy
What You Need to Know Before You Apply
What is the purpose of this trial?
The aims of the DCM Precision Medicine Study are to test the hypothesis that DCM has substantial genetic basis and to evaluate the effectiveness of a family communication intervention in improving the uptake and impact of family member clinical screening.
Who Is on the Research Team?
Ray Hershberger, MD
Principal Investigator
Ohio State University
Are You a Good Fit for This Trial?
This study is for individuals of any age with dilated cardiomyopathy (DCM), a heart condition where the heart's ability to pump blood is decreased. Participants must not have other detectable causes for DCM, severe untreated hypertension, or active diseases that could cause DCM. They should be able to give consent and communicate in English or Spanish at certain sites.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Recruitment and Baseline Assessment
Recruitment of 1300 DCM probands and baseline cardiovascular clinical screening of 2600 family members
Genetic Testing and Intervention
Genetic testing of probands and affected family members by exome sequencing, return of genetic results, and randomization to intervention for family communication
Follow-up
Participants are monitored for adherence to cardiovascular surveillance recommendations after return of genetic results
What Are the Treatments Tested in This Trial?
Interventions
- Family Heart Talk Booklet
Find a Clinic Near You
Who Is Running the Clinical Trial?
Ray Hershberger
Lead Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Collaborator
National Human Genome Research Institute (NHGRI)
Collaborator